- Home
- GIPR vs EDSA Comparison
GIPR vs EDSA Comparison
Compare GIPR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- EDSA
- Stock Information
- Founded
- GIPR 2015
- EDSA 2015
- Country
- GIPR United States
- EDSA Canada
- Employees
- GIPR N/A
- EDSA N/A
- Industry
- GIPR Real Estate Investment Trusts
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- GIPR Real Estate
- EDSA Health Care
- Exchange
- GIPR Nasdaq
- EDSA Nasdaq
- Market Cap
- GIPR 10.8M
- EDSA 13.8M
- IPO Year
- GIPR 2021
- EDSA N/A
- Fundamental
- Price
- GIPR $2.05
- EDSA $4.05
- Analyst Decision
- GIPR Hold
- EDSA Strong Buy
- Analyst Count
- GIPR 1
- EDSA 2
- Target Price
- GIPR N/A
- EDSA $39.00
- AVG Volume (30 Days)
- GIPR 28.5K
- EDSA 13.5K
- Earning Date
- GIPR 11-12-2024
- EDSA 08-09-2024
- Dividend Yield
- GIPR 22.83%
- EDSA N/A
- EPS Growth
- GIPR N/A
- EDSA N/A
- EPS
- GIPR N/A
- EDSA N/A
- Revenue
- GIPR $9,659,091.00
- EDSA N/A
- Revenue This Year
- GIPR N/A
- EDSA N/A
- Revenue Next Year
- GIPR N/A
- EDSA N/A
- P/E Ratio
- GIPR N/A
- EDSA N/A
- Revenue Growth
- GIPR 74.44
- EDSA N/A
- 52 Week Low
- GIPR $1.93
- EDSA $2.50
- 52 Week High
- GIPR $4.64
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- GIPR 40.09
- EDSA 38.30
- Support Level
- GIPR $2.13
- EDSA $4.00
- Resistance Level
- GIPR $2.10
- EDSA $4.44
- Average True Range (ATR)
- GIPR 0.10
- EDSA 0.25
- MACD
- GIPR 0.00
- EDSA -0.03
- Stochastic Oscillator
- GIPR 22.62
- EDSA 4.77
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in major markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.